In our preclinical study, we investigated the anti‐tumor effect of two AXL inhibitors, bemcentinib and tilvestamab, in vitro and in orthotopically implanted 786‐0 RCC cells in mice. The gene discussed is AXL; the disease is renal cell carcinoma.